Objective: To investigate the efficacy and side effects of anti-CD19 CAR-T cell bridging to
allogeneic hematopoietic stem cell transplantation (allo-HSCT) regimen for refractory B …

Early response could be obtained in most patients with relapsed or refractory B cell
lymphoblastic leukemia (R/R B-ALL) treated with chimeric antigen receptor T-cell (CAR-T) …

Objective: To investigate the long term efficacy and side effects of a donor-derived CD19
chimeric antigen receptor (CAR) T-cell (HI19α-4-1BB-ζ CAR-T) therapy in the treatment of …

Objective: To investigate the outcomes of anti-CD19 CAR-T cell for relapsed and refractory B
cell malignancies. Method: Ten patients with relapsed and refractory B cell acute …

Chimeric antigen receptor (CAR)‑T cell therapy is a novel cellular immunotherapy for
relapsed/refractory (R/R) B acute lymphoblastic leukemia (B‑ALL). However, the survival …

Objective: This study aimed to evaluate the maintenance therapy following an anti-CD19-
CAR T-cell therapy for a B-cell acute lymphoblastic leukemia (ALL) patient who relapsed …

Objective: To investigated the safety and efficacy of donor-derived CD19+ or sequential
CD19+ CD22+ chimeric antigen receptor T-cell (CAR-T) therapy in patients with B-cell acute …

Objective: This study aims to investigate the efficacy and safety of chimeric antigen receptor
(CAR) T-cell bridging allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the …

Objective To investigate the efficacy of CD19-targeted chimeric antigen receptor T-cell
(CD19-CAR T) in the treatment of patients with refractory relapsed B cell acute lymphocyte …

Introduction: The prognosis of refractory/relapsed acute lymphoblastic leukemia (ALL) is
poor with chemotherapy or even allogeneic hematopoietic stem cell transplantation (HSCT) …